The abstract is read at the publisher; the summary is JClub's.
In mismatch repair-deficient colorectal cancer, T H 1-like spatial immune architectures are linked to response to anti-PD-1 immunotherapy, unlike regulatory T-dominant interactions in mismatch repair-proficient tumors.
- Why it matters: Immunotherapy gains may depend on how peripheral CD4+ T cells are amplified and recruited, but the spatial differentiation programs that shape early effector responses are not well defined.
- What they did: Using imaging mass cytometry in patients with CRC, the study mapped T cell spatial interactions and performed clonal analyses; in pMMR CRC mouse models, it tested combined OX40 agonist plus PD-1 blockade.
- The result: After PD-1 blockade, stem-like CD4+ T cells differentiated into T H 1-like cells, and in pMMR mice the combination suppressed tumor progression by expanding Il7r+ early effector CD4+ intermediates, enhancing migration toward T H 1-like cells, and inducing interferon-γ–dependent monocyte-macrophages and CD8+ effector T cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.